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Post-Effectiveness of Radiofrequency
atheter Ablation for Atrial Fibrillation
aul S. Chan, MD, MSC,*† Sandeep Vijan, MD, MSC,†‡ Fred Morady, MD,* Hakan Oral, MD*
nn Arbor, Michigan
OBJECTIVES We sought to compare the cost-effectiveness of left atrial catheter ablation (LACA),
amiodarone, and rate control therapy in the management of atrial fibrillation (AF).
BACKGROUND Left atrial catheter ablation has been performed to eliminate AF, but its cost-effectiveness is
unknown.
METHODS We developed a decision-analytic model to evaluate the cost-effectiveness of LACA in 55-
and 65-year-old cohorts with AF at moderate and low stroke risk. Costs, health utilities, and
transition probabilities were derived from published literature and Medicare data. We
performed primary threshold analyses to determine the minimum level of LACA efficacy and
stroke risk reduction needed to make LACA cost-effective at $50,000 and $100,000 per
quality-adjusted life-year (QALY) thresholds.
RESULTS In 65-year-old subjects with AF at moderate stroke risk, relative reduction in stroke risk with
an 80% LACA efficacy rate for sinus rhythm restoration would need to be 42% and 11%
to yield incremental cost-effectiveness ratios (ICERs) $50,000 and $100,000 per QALY,
respectively. Higher and lower LACA efficacy rates would require correspondingly lower and
higher stroke risk reduction for equivalent ICER thresholds. In the 55-year-old moderate
stroke risk cohort, lower LACA efficacy rates or stroke risk reduction would be needed for the
same ICER thresholds. In patients at low stroke risk, LACA was unlikely to be cost-effective.
CONCLUSIONS The use of LACA may be cost-effective in patients with AF at moderate risk for stroke, but
it is not cost-effective in low-risk patients. Our threshold analyses may provide a framework
for the design of future clinical trials by providing effect size estimates for LACA efficacy
needed. (J Am Coll Cardiol 2006;47:2513–20) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.01.070Cardiology Foundation
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mtrial fibrillation (AF) is the most common sustained
ardiac arrhythmia and is associated with significant mor-
idity and mortality (1,2). Recent randomized trials have
emonstrated that, among patients with AF who were at
isk for thromboembolic events, rhythm control with anti-
rrhythmic drugs was not associated with an improved
urvival when compared with rate control (3,4). However,
he ability of antiarrhythmic therapy to maintain sinus
hythm beyond one year was limited in these studies (5),
nd subsequent post-hoc analyses have shown that patients
ho remained in sinus rhythm, regardless of the treatment
trategy, had fewer strokes (6) and better survival (7) than
atients who had recurrent AF, suggesting that the benefi-
ial effects of sinus rhythm may have been offset by the
dverse effects of antiarrhythmic therapy (7).
Left atrial catheter ablation (LACA) that encircles the
ulmonary veins 1 to 2 cm from their ostia with additional
inear lesions has been reported to be effective in maintain-
ng sinus rhythm in patients with AF (8–10). Compared
ith the use of antiarrhythmic therapy, LACA has been
emonstrated to improve quality of life and survival in a
onrandomized, consecutive series of 1,171 patients (10).
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blation techniques, and they both a consulting relationship with Biosense-Webster.c
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006, accepted January 30, 2006.here are significant upfront costs and a risk of infrequent
ut severe complications with LACA. However, the poten-
ial benefits in stroke reduction of maintaining sinus rhythm
ithout the adverse effects of antiarrhythmic drugs may
ustify the high initial costs when compared with medical
herapy in patients with AF.
To date, randomized trials comparing ablation and med-
cal therapy in patients with AF have not looked at “hard”
nd points such as stroke and death. Despite this, more
atients are undergoing LACA treatment for AF. Given
he cost of LACA, clinical trials are needed that examine
ot only the efficacy of LACA in preventing stroke and
eath but also its cost-effectiveness.
Thresholds for cost-effectiveness have traditionally been
efined as $50,000 to $100,000 per quality-adjusted life-
ear (QALY) (11). Using a decision-analytic model, we
onducted an analysis of the cost-effectiveness of LACA
herapy for AF. Our primary focus was to examine the
egree of stroke reduction, across levels of baseline stroke
isk, at which LACA would be cost-effective.
ETHODS
odel design and main outcomes. We constructed a
arkov decision analysis model to assess the cost-
ffectiveness of rhythm control with LACA versus two more
tandards approaches: rhythm control with amiodarone and
edical rate control therapy. We examined hypotheticalohorts of patients with AF who were at low and moderate
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Cost-Effectiveness of AF Ablation June 20, 2006:2513–20isk for stroke (Fig. 1). Short- and long-term outcomes;
dverse events, including stroke, hemorrhage, drug toxicity,
nd procedural complications; and the attendant costs and
tilities for each treatment strategy and health state were
racked (Appendix). The cycle length was three months,
nd all patients were followed until death. All analyses took
he societal perspective.
For the primary threshold analysis, the efficacy and stroke
isk reduction needed for LACA to be cost-effective at
50,000 and $100,000 per QALY were determined. In
ddition, sensitivity analysis was performed to assess the
mpact of other variables on cost-effectiveness. TreeAge Pro
Williamstown, Massachusetts) was used for model design
nd analyses.
reatment strategies. RHYTHM CONTROL BY LACA. The
se of LACA to eliminate AF has been performed using a
ariety of techniques. The efficacy of LACA, after account-
ng for reablations in the first year for AF recurrence and
reatable atrial flutters, has been reported to range from 65%
o 95% (8–10,12,13). Because LACA efficacy (relative to
edical therapy) in restoring sinus rhythm remains un-
nown without direct large trial comparisons, we examined
wide range of efficacy rates for our threshold analyses. In
he base case, we assumed an efficacy rate of 80% (with a
0% redo rate during the first year) and an annual relapse
Abbreviations and Acronyms
AF  atrial fibrillation
ICER  incremental cost-effectiveness ratio
LACA  left atrial catheter ablation
QALY  quality-adjusted life-years
igure 1. Simplified diagram of the Markov decision-analytic model. Th
epresents the Markov process, which leads to one of many health states.
ell, stroke, hemorrhage, drug toxicity, reversion to atrial fibrillation—not
he branch from Well illustrates these chance events. Health states in the fidisabled” includes separate health states in atrial fibrillation or sinus rhythm with
atheter ablation [LACA] complications, or drug toxicity). ICH  intracranialate back to AF of 2% (Appendix) (8,10,13).
ATE CONTROL. On the basis of a previous study (14), a
ombination of digoxin and atenolol was used for rate control
herapy in this model. Because clinical trials have shown that
atients with AF allocated to rate control therapy do convert to
inus rhythm (3,4), we estimated initial rates of conversion to
inus rhythm of 38%, and modeled an annual relapse rate of
% to AF thereafter (Appendix).
HYTHM CONTROL WITH AMIODARONE THERAPY. Rhythm
ontrol with amiodarone also was modeled for our analysis
Appendix). Amiodarone was chosen because its efficacy
nd safety profile are well established, and because it has
een shown to be more effective than other antiarrhythmic
gents (15–18).
arget population. Treatment strategies were assessed in a
ypothetical 65-year-old cohort at either low or moderate
isk of stroke. Patients at moderate risk of stroke were
efined as having one risk factor (hypertension, diabetes
ellitus, coronary artery disease, or congestive heart failure),
hereas patients at low risk of stroke had no risk factors. An
ge of 65 years was chosen because the prevalence of AF is
ependent on age and begins to increase significantly after
he age of 65 years (1). Because the mean age of patients
ho undergo an ablation procedure is 50 to 55 years with
ne risk factor in large series (8,10), a hypothetical cohort of
5-year-old patients at moderate risk for stroke also was
ncluded. Patients who had 2 risk factors for stroke were
onsidered to be at high risk and were excluded from the
nalysis because, thus far, they are atypical of patients who
ndergo a catheter ablation procedure for AF. Overall, three
ohorts were analyzed (Table 1).
are at the left represents the three treatment strategy choices. The M
ircles represent chance events that may occur in each cycle (e.g., remain
n) and results in continued good health or one of several disabling states.
are simplified, and each represents multiple states in the actual model (e.g.,e squ
The c
show
guremild or moderate-to-severe disability due to stroke, hemorrhage, left atrial
hemorrhage.
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June 20, 2006:2513–20 Cost-Effectiveness of AF AblationIn all treatment arms, patients received antithrombotic or
nticoagulant therapy. Patients at moderate risk of stroke
eceived warfarin, whereas patients at low risk of stroke
eceived either warfarin or aspirin. Patients with sinus
hythm restored continued warfarin therapy for six more
onths before transitioning to the use of aspirin. Patients
ith absolute indications or contraindications for anti-
hrombotic therapy were excluded from the analysis. In
ddition, patients who had intractable symptoms or a need
or urgent or emergent cardioversion were not included.
robabilities and rates. The derivation of base-case values
nd range of the estimates for model variables are summa-
ized in the Appendix. The following variables in the model
eserve special emphasis.
TROKE. On the basis of previous studies, including a
ecent meta-analysis, patients in AF at moderate and low
isk for stroke have annual baseline stroke risks (i.e., without
ntithrombotic therapy) of 3.0% and 1.4%, respectively
2,19,20). Aspirin has been found to reduce annual stroke
isk by 22% (2,21–23), and warfarin confers additional risk
eductions of 45% and 35% compared with aspirin therapy
n patients at moderate and low risk, respectively (24).
herefore, our model incorporated annual stroke risks of
.3% and 1.1% for aspirin therapy and 1.3% and 0.7% for
arfarin therapy for patients in AF at moderate and low risk
or stroke, respectively. Finally, because risk increases with
ge, stroke risk was adjusted linearly with a relative risk of
.4 for each decade of age (21,25,26).
The annual risk of stroke in patients with AF restored to
inus rhythm is unknown. The Framingham study cohort
eports an age-adjusted stroke incidence rate of 0.5%/year in
atients without AF (27). Two cohort studies have both
eported stroke rates in predominantly low-risk AF patients
ith sinus rhythm restored of 0.2% per year (28,29).
owever, because these studies were small, nonrandomized
ohort studies with potential selection bias, we conducted
able 1. Atrial Fibrillation Study Cohorts and Treatment
trategies
Stroke Risk Treatment Strategy
oderate LACA  warfarin
Amiodarone  warfarin
Rate control  warfarin
oderate (age  55 yrs) LACA  warfarin
Amiodarone  warfarin
Rate control  warfarin
ow LACA  warfarin
LACA  aspirin
Amiodarone  warfarin
Amiodarone  aspirin
Rate control  warfarin
Rate control  aspirin
hree cohorts were examined with different treatment strategies coupled with
arfarin or aspirin. All models are for a hypothetical 65-year-old cohort, except where
ndicated.
LACA  left atrial catheter ablation.ur primary threshold analyses on this variable to better gssess its impact on cost-effectiveness (Appendix).
ORTALITY. Mortality was age-adjusted with life tables from
he National Center for Health Statistics (30), and noncere-
rovascular mortality was further modified by a relative risk of
.3 and 2.3 in patients without and with moderate-to-severe
isability (from stroke or intra-cranial bleed), respectively
2,20,21) (Appendix). Furthermore, the model incorporated
elative risk reductions of 17% and 33% in nonstroke
ascular mortality by aspirin and warfarin, respectively (2).
OST AND UTILITIES. All health care costs are presented in
004 U.S. dollars; costs and life expectancy were discounted
t 3% per year. Cost estimates were based on Medicare
eimbursement rates (professional and facility costs), hospi-
al accounting information, inflation-adjusted values from
he published literature, and the Red Book for wholesale
rug costs (Appendix) (11,31). The annual cost of warfarin
herapy included every four-week serum monitoring and a
roblem-focused office visit (CPT code 99213), whereas
igoxin therapy included biannual serum monitoring (32).
lthough atrioesophageal fistula is a rare event with abla-
ion therapy, it was estimated to cost $50,000 and have a
0% mortality rate.
The quality of life for warfarin and aspirin therapies and
ndividual health states were obtained from published liter-
ture (Appendix) (2,20,33–35). Short-term disutilities were
pplied for clinical events (stroke, hemorrhage, drug toxic-
ty, and complications for ablation) by applying a disutility
alue of 0.5 for the duration of the event. A half-cycle
orrection for both costs and utilities was used to avoid
verestimation of expected survival in the model (11).
ENSITIVITY ANALYSIS. We assigned estimates for one-year
ACA efficacy of 80% and annual stroke risk in patients
ith restored sinus rhythm using estimates from the liter-
ture (Appendix); these variables were examined in special
etail using threshold analyses. We also conducted one-way
ensitivity analyses for all other variables in the model. Multi-
ariate sensitivity analyses were then conducted using second
rder Monte Carlo simulation, whereby the distribution of
anges of every model variable is repeatedly sampled to esti-
ate the distribution of cost-effectiveness estimates (11). For
his simulation, 10,000 trials for each AF cohort were per-
ormed. A normal distribution encompassing four standard
eviations for the estimate range was used for most variables.
or skewed data (e.g., costs of hospitalizations and rates of
omplications), a log-normal distribution was assumed.
ESULTS
ase-case analysis. Using the assigned estimates for
ACA efficacy and annual stroke risk in sinus rhythm
Appendix), the cost-effectiveness values of each treatment
trategy stratified according to the risk of stroke are shown
n Table 2. When the stroke risk was low, antithrombotic
herapy with aspirin dominated therapy with warfarin re-
ardless of the treatment strategy (data not shown).
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Cost-Effectiveness of AF Ablation June 20, 2006:2513–20Among 65 year-old patients at moderate risk for stroke,
ACA (11.06 QALYs) was more effective than rate control
10.81 QALYs) and rhythm control with amiodarone
10.75 QALYs). However, LACA was more costly
$52,369) than amiodarone therapy ($43,358) and rate
ontrol ($39,391). Because amiodarone was both less effec-
ive and more costly, it was dominated by rate control
herapy. Compared with rate control, LACA was associated
ith an incremental cost-effectiveness ratio (ICER) of
51,800 per QALY (Table 2). Likewise, among 55-year-old
atients at moderate risk for stroke, a rate control strategy
ominated amiodarone therapy, and LACA had an ICER
f $28,700 per QALY compared with rate control. For
atients at low risk for stroke, LACA had an ICER of
98,900 per QALY.
ain threshold analyses. Because rate control therapy
ominated amiodarone therapy in all cohorts, and because
ACA had an ICER $100,000 per QALY compared
ith medical therapy for AF patients at low risk of stroke,
e focused our threshold analyses to comparisons between
ACA and rate control therapy for the moderate-risk
ohorts.
In the 65-year-old moderate-risk cohort, $50,000 and
100,000 per QALY thresholds with varying LACA effi-
acy and annual stroke risks in sinus rhythm are depicted in
igure 2A. At the base-case estimate of 80% for one-year
ACA efficacy, an annual stroke risk in sinus rhythm of
0.76% and 1.15% would yield ICERs less than $50,000
nd $100,000 per QALY. Thus, the relative risk of stroke
ith long-term sinus rhythm would need to decrease by
2% and 11%, respectively, compared with patients in AF
n warfarin (1.3% per year), to yield ICERs below these
hresholds. As LACA efficacy decreases, the stroke risk
eduction with long-term sinus rhythm would need to
ncrease for the same corresponding ICER threshold.
ACA efficacy rates less than 75% and 60% would require
50% stroke risk reduction with long-term sinus rhythm
o yield ICER thresholds of $50,000 and $100,000 per
ALY, a scenario that may be implausible. Similarly,
igure 2B depicts threshold analyses for the 55-year-old
able 2. Incremental Cost-Effectiveness Ratios (ICER) in Base-C
Stroke Risk Strategy
oderate (age  65 yrs) Rate control  warfarin $
Amiodarone  warfarin $
LACA  warfarin $
oderate (age  55 yrs) Rate control  warfarin $
Amiodarone  warfarin $
LACA  warfarin $
ow Rate control  ASA $
Amiodarone  ASA $
LACA  ASA $
alculations for cost-effectiveness were performed by taking the incremental cost (
difference between quality-adjusted life-years [QALYs] of compared strategies). No
ostly than the reference strategy. All ICER results are measured in 2004 U.S. dollar
o round-off error.
ASA  aspirin; LACA  left atrial catheter ablation.oderate stroke risk cohort. Not surprisingly in this cohort,
c
tower LACA efficacy rates are needed to satisfy the $50,000
nd $100,000 per QALY thresholds, as younger patients
ive longer (Table 2) and are therefore exposed to higher
ifetime risk for stroke and hemorrhage from anticoagulant
herapy.
Because our model used conservative estimates (biased
gainst LACA therapy) for the cardioversion rate with rate
ontrol therapy (38%), health state utility for patients in AF
1.0), and annual cost for rate control therapy ($400), we
epeated the threshold analyses with less conservative esti-
ates in the 65-year-old moderate risk cohort for a $50,000
er QALY threshold (Fig. 3). In each instance, lower
Estimates, Stratified by Ischemic Stroke Risk
Life-Years QALYs ICER ($/QALY)
1 11.47 10.81 Reference
8 11.45 10.75 Dominated
9 11.55 11.06 $51,800/QALY
9 14.80 13.95 Reference
5 14.75 13.81 Dominated
0 14.88 14.26 $28,700/QALY
0 11.65 11.21 Reference
5 11.60 11.02 Dominated
6 11.70 11.40 $98,900/QALY
nce between costs of compared strategies) divided by the incremental effectiveness
tions are needed for strategies that are dominated, as they are less effective and more
are rounded off to the nearest $100. Discrepancies in the ICER calculations are due
igure 2. Main threshold analyses. Varying left atrial catheter ablation
LACA) efficacy rates and annual stroke risks with normal sinus rhythm
NSR) restoration are determined for incremental cost-effectiveness
hresholds of $50,000 (diamonds) and $100,000 (squares) per quality-
djusted life-year for 65-year-old (A) and 55-year-old (B) subjects at
oderate risk for stroke. For each LACA efficacy rate, LACA would bease
Cost
39,39
43,35
52,36
50,50
55,79
59,38
24,54
38,42
43,03
differe
calcula
s andost-effective at a specific threshold with stroke risks at or below the
hreshold lines.
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June 20, 2006:2513–20 Cost-Effectiveness of AF AblationACA efficacy rates or stroke risk reduction would be
eeded compared to the base-case estimate.
ne-way sensitivity analysis. The results of one-way sen-
itivity analyses over a wide range of estimates for patients at
oderate risk for stroke are shown in Figure 4. The most
nfluential variables in the one-way sensitivity analyses were
he risk of stroke in AF with warfarin, the discount rate,
ACA cost, the utility and hemorrhage risk with warfarin
herapy, the rate of recurrence of AF after LACA, and the
onversion rate to sinus rhythm with rate control therapy. In
o instance did the incremental cost-effectiveness range
xceed $95,000 per QALY with these variables in either age
ohort in one-way sensitivity analyses.
ultivariate sensitivity analysis. Monte Carlo simula-
ions using base-case estimates within each cohort demon-
trated that, with the 55-year-old moderate stroke risk
igure 3. Threshold analyses using less conservative model estimates.
hreshold analyses were repeated with less conservative estimates for
ormal sinus rhythm (NSR) restoration with rate control therapy (A),
ealth state utility for atrial fibrillation (B), and annual cost of rate control
herapy (C). Analyses shown are for the 65-year-old moderate stroke-risk
ohort for a $50,000 per quality-adjusted life-year cost-effectiveness
hreshold. Diamonds  base-case; squares  less conservative estimate;
ACA  left atrial catheter ablation.ohort, the ICER comparing LACA with rate control cherapy had a 4% probability of being $100,000 per
ALY gained, and an 82% probability of being $50,000
er QALY gained (Table 3). As expected, among the
5-year-old moderate stroke risk cohorts, the thresholds for
ost-effectiveness were less certain, with 22% of simulations
$100,000 per QALY gained and only 40% of simulations
$50,000 per QALY gained.
ISCUSSION
his study provides a framework to assess the potential
ost-effectiveness of ablation therapy in patients with AF.
or moderate stroke-risk cohorts, LACA may be cost-
ffective if sinus rhythm restoration translates into lower
ates of stroke and anticoagulant-related hemorrhage. At
ur base-case one-year LACA efficacy estimate of 80%,
elative stroke risk reductions with sinus rhythm restoration
f 42% and 11% would yield ICERs less than the thresholds
f $50,000 and $100,000 per QALY, respectively. Not
urprisingly, the relative stroke risk reductions with sinus
hythm restoration are inversely related to LACA efficacy.
n patients at low risk of stroke, LACA therapy does not
ppear to be cost-effective unless the reduction in stroke risk
s implausibly large. Our base-case estimates yielded an
CER $100,000 per QALY, with resultant multivariable
ensitivity analyses showing that only 40% of all simulations
ould be $100,000 per QALY (results not shown).
owever, only a minority of patients with AF are consid-
red to be at low risk for stroke (“lone AF”) (36) because the
ajority of patients will have at least one stroke risk factor.
mportantly, by identifying minimum levels of LACA
fficacy required for various cost-effectiveness thresholds,
ur analyses can help guide future clinical trials to determine
stimates of effect sizes and study sample sizes needed to
emonstrate both efficacy and cost-effectiveness.
No previous studies have assessed the cost-effectiveness of
atheter ablation of AF. Rhythm control with antiarrhyth-
ic drug therapy was compared with a rate control strategy
n previous studies (2,15,33). In these studies, rhythm
ontrol was found to be more cost-effective than rate
ontrol. However, patients in the rate control strategy were
ssumed to remain in AF throughout their Markov cycles
nd, contrary to the observations from recent clinical trials
3,4), spontaneous cardioversions were not considered to
ccur in the model. We included these events in our
odel and found that rhythm control with amiodarone
as dominated by rate control, consistent with the
ndings of a recent cost-effectiveness analysis of the
trial Fibrillation Follow-Up Investigation of Rhythm
anagement (AFFIRM) trial (37).
The issue of cost-effectiveness for novel procedures such
s LACA over long-term drug therapy is important to
onsider before clinical adoption of and reimbursement for
he procedure. In this study, we took a conservative ap-
roach to assess the cost-effectiveness of LACA. First, the
onversion rate to sinus rhythm with rate control therapy
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Cost-Effectiveness of AF Ablation June 20, 2006:2513–20as biased in its favor, because we used published rates that
ncluded a significant percentage of patients that crossed
ver to antiarrhythmic therapy in the rate control group.
econd, several studies prospectively comparing AF ablation
ith rate control therapy have demonstrated significant
linical improvements in quality of life in those treated with
blation (10,38,39). Because no validated health state utility
easurements were performed in those studies, our model
ssumed similar health utility estimates for patients in sinus
hythm and in AF. Third, calcium channel blocker agents
ften are used in rate control therapy of patients with AF,
ut our model assessed the less expensive combination of
tenolol and digoxin for a conservative estimate of cost in
he rate control group. Fourth, most patients referred for
ACA therapy have failed previous antiarrhythmic therapy.
s such, we may have underestimated the true efficacy of
ACA in our comparisons with the rate control and
miodarone strategies. In our sensitivity analyses with less
onservative assumptions, it is not surprising that we found
hat lower LACA efficacy rates and lower reduction in
troke risk were needed to yield ICERs $50,000 per
ALY.
igure 4. Tornado diagram of variables with significant influence on increm
n one-way sensitivity analysis with the largest impact on incremental cos
LACA) with rate control therapy for 65-year-old (solid bars) and 55-year
uality-adjusted life-year.
able 3. Multivariable Sensitivity Analyses
$50K/QALY $100K/QALY $80K
ge 65 yrs 40% 78% 6
ge 55 yrs 82% 96% 9
ensitivity analyses with Monte Carlo simulation were conducted by repeated sampl
brillation cohorts at moderate risk of stroke, 10,000 trials were performed compari
ost-effectiveness estimates below various thresholds is given.
K  thousand; QALY  quality-adjusted life-year.In our model, LACA consisted of encircling lesions
round the pulmonary veins. However, AF also may be
ffectively eliminated using a variety of other approaches
40–42). Sensitivity analysis over a wide range of efficacy
ates suggests that the threshold efficacy rates to render
atheter ablation therapy for AF cost-effective at $100,000
er QALY are at or lower than the widely reported success
ates with these alternative ablation techniques. However,
ithout clinical trials looking at “hard” end points, the
ost-effectiveness of ablation therapy for AF remains un-
nown. Nonetheless, the analyses in this study probably are
pplicable to the majority of left atrial radiofrequency
atheter ablation procedures used to eliminate AF.
Traditionally, an ICER of $50,000 per QALY has been
sed to determine whether therapies are considered cost-
ffective, based on previous studies for hemodialysis (43).
ecently, some have argued that ICERs of $100,000 and
150,000 per QALY are acceptable (11,44). Moreover, we
ecognize that a therapy’s true cost-effectiveness should
ncorporate not only determination of ICERs but also the
ctual cost of the therapy and the disease burden in the
eneral population. Finally, we caution that these results
cost-effectiveness for the moderate stroke-risk cohorts. Variables identified
ctiveness are depicted. The analysis compares left atrial catheter ablation
ruled bars) moderate stroke-risk cohorts. AF  atrial fibrillation; QALY 
illingness to Pay
LY $60K/QALY $40K/QALY $20K/QALY
52% 25% 1%
87% 72% 38%
ross the ranges of parameter estimates for all model variables. For each of the atrial
CA with rate control therapy. The percentage of the simulations with incrementalental
t-effeW
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June 20, 2006:2513–20 Cost-Effectiveness of AF Ablationhould be interpreted in the context of a lifetime model.
hould future clinical trials find LACA to be efficacious in
educing morbid events and even death, our model assumes
hat the benefits seen with sinus rhythm restoration are
ustained beyond the typical trial duration. This is an
ssumption that all decision-analytic models make when
sing lifetime horizons. Not surprisingly, when we exam-
ned a 5- and 10-year time horizon for the base-case
stimates for our moderate stroke-risk cohorts, we found
hat LACA appears less cost-effective, given that LACA
as significant upfront costs (Appendix).
tudy limitations. Our study had other limitations. Ami-
darone was used as the choice of antiarrhythmic agent for
he third therapy arm. A drug with a better adverse effect
rofile may have been more cost-effective. However, amio-
arone is more effective than the majority of antiarrhythmic
gents, and a lower efficacy of another drug would probably
egate the beneficial effects of a better side effect profile.
inally, our model was developed only in 55- and 65-year-
ld cohorts and, therefore, the findings may not apply to
ounger or older patients. However, it is likely that LACA
ill be more cost-effective in younger patients, who have a
onger life expectancy, as long as LACA is not associated
ith long-term deleterious effects or a high late-recurrence
ate. On the other hand, LACA would be expected to be
ess cost-effective in patients older than 65 years because the
nherent risk of stroke may be higher regardless of whether
he patient is in AF or sinus rhythm.
onclusions. In patients with AF, LACA is unlikely to be
ost-effective in patients at low risk for stroke. In moderate-
isk patients, LACA may be cost-effective if sufficiently
igh LACA efficacy rates in restoring sinus rhythm translate
nto lower morbidity. Our analyses may help in designing
uture clinical trials that compare ablation with medical
herapy by providing estimates for LACA efficacy and
troke risk reduction needed in order to demonstrate both
linical efficacy and cost-effectiveness.
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